preclinical antibodies
Bristol Myers Squibb Invests $100M in BioArctic for Next-Generation Alzheimer’s Therapies
Alzheimer’s disease, Bristol Myers Squibb, BioArctic, Leqembi, preclinical antibodies, BAN1503, BAN2803
Actionable Insights Powered by AI
Alzheimer’s disease, Bristol Myers Squibb, BioArctic, Leqembi, preclinical antibodies, BAN1503, BAN2803